Actividades preventivas en la mujer - papps
Actividades preventivas en la mujer - papps
Actividades preventivas en la mujer - papps
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Del Cura-González I, et al.<br />
<strong>Actividades</strong> <strong>prev<strong>en</strong>tivas</strong> <strong>en</strong> <strong>la</strong> <strong>mujer</strong><br />
GRUPOS DE EXPERTOS DEL PAPPS<br />
46. Gr<strong>en</strong>ader T, Peretz T, Lifchitz M, Shavit L. BRCA1 and BR-<br />
CA2 germ-line mutations and oral contraceptives: to use or not<br />
to use. Breast. 2005;14:264-8.<br />
47. Fernández E, La Vecchia C, Balducci A, Chat<strong>en</strong>oud L, Franceschi<br />
S, Negri E. Oral contraceptives and colorectal cancer risk: a<br />
meta-analysis. Br J Cancer. 2001;84:722-7.<br />
48. Pfahlberg A, Hassan K, Wille L, Laus<strong>en</strong> B, Geffeller O. Systematic<br />
review of case-control studies: oral contraceptive show no<br />
effect on me<strong>la</strong>noma risk. Public Health Reviews. 1997;25:309-<br />
15.<br />
49. Hannaford P, Webb AM. Evid<strong>en</strong>ce-guide prescribing of the pill.<br />
London: Parth<strong>en</strong>on; 1996.<br />
50. Sociedad Españo<strong>la</strong> de Contracepción. Confer<strong>en</strong>cia de Cons<strong>en</strong>so.<br />
Prescripción y manejo de anticonceptivos hormonales orales.<br />
Toledo: Sociedad Españo<strong>la</strong> de Contracepción; 1997.<br />
51. Hannaford P, Webb AM. Evid<strong>en</strong>ce-guide prescribing of combined<br />
oral contraceptives: cons<strong>en</strong>sus statem<strong>en</strong>t. Contraception.<br />
1996;54:125-9.<br />
52. Stewart FH, Harper CC, Ellerston CE, Grimes DA, Sawaya<br />
GF, Trussell J. Clinical breast and pelvis examination requerim<strong>en</strong>ts<br />
for hormonal contraception. JAMA. 2001;285:2232-9.<br />
53. Actualización del manejo clínico de <strong>la</strong> anticoncepción intrauterina.<br />
Recom<strong>en</strong>daciones de <strong>la</strong> Confer<strong>en</strong>cia de Cons<strong>en</strong>so. Progresos<br />
Obstet Ginecol. 2002;45:457.<br />
54. Lete I, Martínez F, Álvarez JD. Anticoncepción intrauterina.<br />
Manejo clínico. En: Lete I, editor. Curso de habilidades <strong>en</strong> anticoncepción<br />
para médicos de at<strong>en</strong>ción primaria y p<strong>la</strong>nificación<br />
familiar. Sociedad Españo<strong>la</strong> de Contracepción. Madrid: SEC;<br />
1999. p. 95-101.<br />
55. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F,<br />
Guzmán-Rodríguez R. Use of cooper intrauterine devices and<br />
the risk of tubal infertility among nulligravid wom<strong>en</strong>. N Engl J<br />
Med. 2001;345:608-9.<br />
56. Darney P. Time to pardon the DIU? N Engl J Med. 2001;345:<br />
608-9.<br />
57. Martínez F, Giménez E, Hernández G, et al. Experi<strong>en</strong>ce with<br />
gynefix insertions in spain: favorable acceptance of the intrauterine<br />
contrapceptive imp<strong>la</strong>nt with some limitations. Contraception.<br />
2002;66:315-20.<br />
58. O’Bri<strong>en</strong> PA, Marfleet C. Frameless versus c<strong>la</strong>ssical intrauterine<br />
device for contraception. Cochrane Database Syst Rev.<br />
2005;(1):CD003282. Review.<br />
59. Shelton JD. Risk of clinical pelvic inflmatory disease attributable<br />
to an intrauterine device. Lancet. 2001;357:443.<br />
60. Grimes DA, Schulz KF. Antibiotic prophy<strong>la</strong>xis for intrauterine<br />
contraceptive device insertion (Cochrane Review). En: The<br />
Cochrane Library, Isuue 4. Oxford: Update Software; 2000.<br />
61. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer<br />
MJ, Rosner B, et al. Tubal sterilization, hysterectomy and risk of<br />
ovarian cancer. A prospective study. JAMA. 1993;270:2813.<br />
62. Bernal E, Latour J, Pradas F, Gómez LI. The association betwe<strong>en</strong><br />
vasectomy and prostate cancer: a systematic review of the literature.<br />
Fertil Steril. 1998;70:191-200.<br />
63. Popu<strong>la</strong>tion Information Program, C<strong>en</strong>ter for Communication<br />
Program, The Johns Hopkins university School of Public Health.<br />
2000(28)1. Disponible <strong>en</strong>: www. Jhuccp.org<br />
64. Álvarez D, Arribas L, Cabero L, Lete I, Ollé C, De Lor<strong>en</strong>zo R.<br />
Guía de actuación e anticoncepción de emerg<strong>en</strong>cia. La píldora<br />
del día después. Barcelona: Pulso Ediciones; 2002.<br />
65. Von Hertz<strong>en</strong> H, Piaggio H, Ding J, et al. Low dose mifepristone<br />
and two regim<strong>en</strong>s of levonorgestrel for emerg<strong>en</strong>cy contraception:<br />
a WHO multic<strong>en</strong>tre randomised trial. Lancet. 2002;360:<br />
1803-10.<br />
66. Webbs A. Emerg<strong>en</strong>cy contraception. BMJ. 2003;326:775-6.<br />
67. Bailon E, Arribas L. La píldora del día después: una segunda<br />
oportunidad. At<strong>en</strong> Primaria. 2002;29:430-32.<br />
68. Free C, Lee R, Ogd<strong>en</strong> J. Young womwn’s account of factors in-<br />
flu<strong>en</strong>cing their use and non-use of emerg<strong>en</strong>cy contraception: indepth<br />
interview study. BMJ. 2002;325:1393-7.<br />
69. Ch<strong>en</strong>g L, Gülmezoglu AM, Ezcurra E, Van Look PFA. Interv<strong>en</strong>tions<br />
for emerg<strong>en</strong>cy contraception (Cochrane Review). En:<br />
The Cochrane Library, Isuue 4.Oxford: Update Software; 2000.<br />
70. Kahn JG, Becker BJ, MacIsaa L, Amory JK, Neuhaus J, Olkin I,<br />
et al. The efficacy of medical abortion: a meta-analysis. Contraception.<br />
2000;61:29-40.<br />
71. Neilson JP. Mifepristone for induction of <strong>la</strong>bour (Cochrane Review).<br />
En: The Cochrane Library, Issue 4. Oxford: Update Software;<br />
2000.<br />
72. Counselling to prev<strong>en</strong>t Unint<strong>en</strong>ded Pregnancy. En: US Prev<strong>en</strong>tive<br />
Services Task Force. Guide To clinical prev<strong>en</strong>tive services.<br />
2nd ed. Baltimore: Williams& Wilkins; 1996. p. 739-53.<br />
73. Kirby D. Sexuality and sex education at home and school. Adolesc<br />
Med. 1999;10:195-209.<br />
74. Hiller JE, Griffith E. Education for contraceptive use by wom<strong>en</strong><br />
after childbirth (Cochrane Review). En: The Cochrane Library,<br />
Issue 4. Oxford: Update Software; 2000.<br />
75. Johson LK, Edelman A, J<strong>en</strong>s<strong>en</strong> J. Pati<strong>en</strong>t satisfaction and the<br />
impact of writt<strong>en</strong> material about postpartum contraceptive decisions.<br />
Am J Obstet Gynecol. 2003;188:1202-4.<br />
76. Quinlivan JA, Box H, Evans SF. Postnatal home visits in te<strong>en</strong>age<br />
mothers: a randomised controlled trial. Lancet.<br />
2003;361:893-900.<br />
77. Davis A, Wysocki S. Clinician/pati<strong>en</strong>t interaction: communicating<br />
the b<strong>en</strong>efits and risks of oral contraceptives. Contraception.<br />
1999;59 Suppl:S39-42.<br />
78. Boyer CB, Schafer MA, Shaffer RA, Brodine SK, Pol<strong>la</strong>ck LM,<br />
Betsinger K, et al. Evaluation of a cognitive-behavioral, group,<br />
randomized controlled interv<strong>en</strong>tion trial to prev<strong>en</strong>t sexually<br />
transmitted infections and unint<strong>en</strong>ded pregnancies in young wom<strong>en</strong>.<br />
Prev Med. 2005;40:420-31.<br />
79. Arribas L, Duarte S, Saavedra AM. Indicación de un método<br />
anticonceptivo a una adolesc<strong>en</strong>te: imp<strong>la</strong>nte subcutáneo de gestág<strong>en</strong>o.<br />
At<strong>en</strong> Primaria. 2004;34:499-502.<br />
80. Haya J, Reyes S, Lertxundi R. Aspectos legales <strong>en</strong> <strong>la</strong> adolesc<strong>en</strong>cia.<br />
En: Grupo de Trabajo sobre Salud Reproductiva <strong>en</strong> <strong>la</strong> Adolesc<strong>en</strong>cia<br />
SEC, editor. Manual de salud reproductiva <strong>en</strong> <strong>la</strong> adolesc<strong>en</strong>cia.<br />
Aspectos básicos clínicos.<br />
81. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion<br />
of intrauterine devices. Cochrane Database Syst Rev.<br />
2004;(4):CD001777. Review.<br />
82. Arribas L, Alemán P, Saavedra AM. Anticoncepción durante el<br />
puerperio y <strong>la</strong> <strong>la</strong>ctancia. FMC. 2005;12:482-7.<br />
83. World Health Organization. Selected practice recomm<strong>en</strong>dations<br />
for contraceptive use. 2nd ed. G<strong>en</strong>eve: WHO; 2005. Disponible<br />
<strong>en</strong>: www.who.int/reproductive-health/<br />
Medidas <strong>prev<strong>en</strong>tivas</strong><br />
<strong>en</strong> el embarazo<br />
E. Bailón-Muñoz, L. Arribas-Mir y J. Landa-Goñi<br />
Las actividades de prev<strong>en</strong>ción y promoción de <strong>la</strong> salud <strong>en</strong><br />
<strong>la</strong> at<strong>en</strong>ción maternoinfantil son incuestionables, por <strong>la</strong><br />
bu<strong>en</strong>a re<strong>la</strong>ción coste-b<strong>en</strong>eficio que pres<strong>en</strong>tan <strong>en</strong> resultados<br />
de salud. En los países desarrol<strong>la</strong>dos, <strong>la</strong> tasa de mortalidad<br />
perinatal ha pasado de 16,7 por 1.000 nacidos <strong>en</strong> 1973 a<br />
7,5 por 1.000 nacidos <strong>en</strong> 1992; esta tasa expresa <strong>la</strong> calidad<br />
de <strong>la</strong> at<strong>en</strong>ción durante <strong>la</strong> gestación. En los países <strong>en</strong> vías de<br />
| At<strong>en</strong> Primaria 2005;36(Supl 2):102-30 | 109